Loading...
The aromatase inhibitor exemestane (brand name, Aromasin) is associated with a 65% reduction in the incidence of invasive breast cancer in postmenopausal women at moderately increased risk, according to an industry-funded study in the New England Journal of Medicine.
Researchers randomized roughly 4600 women with at least one major risk factor to daily exemestane or placebo. After a median 35 months' follow-up, the annual incidence of invasive breast cancer was lower in the exemestane group (0.19% vs. 0.55%).
Overall side effects were more common with exemestane, but there was no difference between the groups in cardiovascular or neurologic events; fractures; or new cancers. Menopausal symptoms, as well as menopause-related vasomotor and sexual concerns, were slightly more common among patients taking exemestane.
Comment
LINK(S):
NEJM article (Free)
NEJM editorial (Free)